Author details

Full Name

Peter D Kwong

Affiliation

ORCID

Career Start Year

1989

Papers

418

H Index

109

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36976017	Effect of Passive Administration of Monoclonal Antibodies Recognizing Simian Immunodeficiency Virus (SIV) V2 in CH59-Like Coil/Helical or Î²-Sheet Conformations on Time of SIV Acquisition.		2023
36411391	A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins.	Nat Chem Biol	2023
36382536	Antibodies as drugs-a Keystone Symposia report.	Annals of the New York Academy of Sciences	2023
38042809	Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates.		2023
37766115	Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes.	Vaccines (Basel)	2023
37605043	Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization.	Nat Struct Mol Biol	2023
38019653	High frequency of HIV precursor-target-specific B cells in sub-Saharan populations.		2023
37738240	Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus.	PLoS Pathog	2023
37989731	Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.		2023
37986867	Allosteric Neutralization by Human H7N9 Antibodies.		2023
37986823	Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.	bioRxiv	2023
37553406	Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery.	NPJ Vaccines	2023
37345226	Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain.		2023
36909529	An intact amber-free HIV-1 system for in-virus protein bioorthogonal click labeling that delineates envelope conformational dynamics.		2023
37075126	An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.		2023
36629414	A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.	mBio	2023
37436900	Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.		2023
37436899	HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.	Cell Rep	2023
36931276	Cryo-EM structures of anti-malarial antibody L9 with circumsporozoite protein reveal trimeric L9 association and complete 27-residue epitope.		2023
37296186	Tryptophan-like side chain holding aptamers inhibit respiratory syncytial virus infection of lung epithelial cells.		2023
37295404	Vaccine elicitation and structural basis for antibody protection against alphaviruses.	Cell	2023
36729903	Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.	MAbs	2023
36848985	Rhesus macaque Bcl-6/Bcl-xL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node.		2023
37503026	RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.		2023
37098956	Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.		2023
35324257	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.	Science	2022
35841885	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability.	Structure	2022
35709309	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.	PLoS Pathogens	2022
35589938	Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency.	Scientific Reports	2022
36302375	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.	Cell Reports	2022
35447072	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.	Cell	2022
36356572	Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses.	Immunity	2022
36093348	Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination.		2022
35438546	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses.	Sci Transl Med	2022
36344847	Cryo-EM structures of prefusion SIV envelope trimer.	Nat Struct Mol Biol	2022
36284200	Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.	Scientific Reports	2022
35568025	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.	Cell Rep	2022
35378757	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.	bioRxiv	2022
35489332	Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite.	Structure	2022
35736810	Highly protective antimalarial antibodies via precision library generation and yeast display screening.	Journal of Experimental Medicine	2022
35677079	Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins.	bioRxiv	2022
35609088	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.	PLoS ONE	2022
35413243	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site.	Structure	2022
36257313	Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses.	Cell	2022
36119018	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens.	Frontiers in Immunology	2022
35783486	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.	eClinicalMedicine	2022
35537058	-Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity.	ACS Chemical Biology	2022
36423012	Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1.	Vaccines	2022
36517467	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.	Nat Commun	2022
36582240	Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings.	Front Immunol	2022